On October 3, 2014, ProQR Therapeutics N.V. announced the appointment of Smital Shah as its new Chief Financial Officer, effective immediately. Ms. Shah has a track record of management and leadership experience in the biopharmaceutical industry as well as in investment banking, with a particular focus on financial strategy and capital markets. Ms. Shah joins the company from Gilead Sciences Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | +5.98% | +3.72% | -1.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.52% | 159M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-1.37% | 21.96B | |
-6.73% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N.V. Appoints Smital Shah as Chief Financial Officer